This article was originally published in The Tan Sheet
Impax Labs granted tentative approval for generic loratadine/pseudoephedrine extended-release tablets (Schering-Plough's Claritin-D 12- and 24-Hour) on May 29 and May 24, respectively. Hayward, Calif.-based company believes it was first to file for generic 12-hour formulation. Impax, a defendant in Schering's ongoing loratadine patent litigation, also has a pending ANDA for Claritin Reditabs. In December, Impax entered into an agreement granting Novartis Consumer Health exclusive rights to market an OTC generic version of Claritin to be supplied by Impax, which is in discussions with potential OTC partners for two additional generic loratadine formulations. Novartis' Geneva Pharmaceuticals is believed to be first to file for the loratadine 10 mg tablet dosage form...
You may also be interested in...
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.